AZD9291 First Time In Patients Ascending Dose Study

NCT01802632 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

603

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non Small Cell Lung Cancer
Advanced (Inoperable) Non Small Cell Lung Cancer

Interventions

DRUG: AZD9291

Sponsor

AstraZeneca